Lasa Supergenerics: Trading Window Closed for Q4FY26 Results
Lasa Supergenerics Limited will close its trading window from April 01, 2026. The closure is effective until 48 hours after the declaration of audited financial results for the quarter and year ended March 31, 2026.
The closure of the trading window is a standard procedure before the announcement of financial results and does not have a direct material impact on the company's operations or financial standing.
The announcement is a routine regulatory disclosure regarding the closure of the trading window and does not contain any new financial or business performance information.
Lasa Supergenerics Limited has announced the closure of its trading window for dealing in the company's equity shares. This closure is in accordance with the Company’s Code of Conduct for Regulating, Monitoring and Reporting of Trading by Insiders, as per the Prohibition of Insider Trading Regulations, 2015, as amended.
The trading window will be closed for designated employees and their immediate relatives starting from April 01, 2026. It will remain closed until 48 hours after the declaration of the Audited Financial Results for the quarter and the year ended March 31, 2026, inclusive of both the start and end dates.
The company has informed BSE Limited and the National Stock Exchange of India Limited about this closure. The announcement was made on Monday, March 30, 2026.
What to do with a filing like this
Lasa Supergenerics Limited filed this with the NSE as a statutory disclosure, categorised under trading window disclosure. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Lasa Supergenerics Limited. Read the original for the full detail.